Henry H. Chill

Dr. Henry H. Chill

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
HCHenry H. Chill
Henry H. Chill
GKGilad Karavani
Gilad Karavani
TRTalya Rachmani
Talya Rachmani
UDUri P Dior
Uri P Dior
OTOfer Tadmor
Ofer Tadmor
ASAsher Shushan
Asher Shushan
Uterine leiomyomas are often discovered during early pregnancy and in most cases will have no effect on pregnancy outcomes. However, in rare cases uterine leiomyomas may lead to obstetric complications. The aim of the study was to evaluate rate of uterine leiomyoma growth in the 3 trimesters of pregnancy. We conducted a retrospective cohort study. Included were women who were diagnosed with uterine leiomyoma during pregnancy and had at least two sonographic measurements in different trimesters. Data regarding leiomyoma growth, recorded by ultrasound examination, during 1st 2nd and 3rd trimesters were collected from electronic patient records. Two-hundred forty-eight uterine leiomyomas were included in the study. Leiomyoma area increased substantially in size between the 1st and 2nd trimesters (54.5% ± 75.9%, p = .007) and to a lesser degree between the 2nd and 3rd trimesters (17.9% ± 59.7%, NS). Evaluation of the change in size throughout the pregnancy – between 1st and 3rd trimesters revealed a significant increase of 95.9% ± 191.3% (p < .001). There was no significant growth of the leiomyomas between the 2nd and 3rd trimesters. Uterine leiomyomas tend to grow substantially during the 1st trimester of pregnancy. This trend is attenuated later with minimal growth towards the end of gestation.

28 February 2022 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
ADAharon Dick
Aharon Dick
JRJoshua I Rosenbloom
Joshua I Rosenbloom
EGEinat Gutman-Ido
Einat Gutman-Ido
NLNaama Lessans
Naama Lessans
ACAdva Cahen-Peretz
Adva Cahen-Peretz
HCHenry H. Chill
Henry H. Chill
Background: COVID-19 during pregnancy is associated with adverse outcomes for mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk of symptomatic disease. Several small studies have reported the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effect on obstetric outcomes. Objective: To examine the association between SARS-CoV-2 vaccination during pregnancy and maternal and neonatal outcomes in a large cohort study. Furthermore, to evaluate if timing of vaccination during pregnancy is related to adverse outcomes. Methods: A retrospective cohort study of women who delivered between December 2020 and July 2021 at a large tertiary medical center. Excluded were women with multiple pregnancy, vaccination prior to pregnancy, COVID-19 infection during or before pregnancy, or unknown timing of vaccination. Primary outcomes were the incidence of preterm labor and of small for gestational age. Secondary outcomes were other maternal and neonatal complications. A secondary analysis investigating the association between time of vaccination and outcomes was also performed. Multivariable logistic regression models were used to adjust for potential confounders. Results: There were 5618 women who met the inclusion criteria: 2,305 (41%) women were vaccinated and 3,313 (59%) were unvaccinated. There were no differences between vaccinated and non-vaccinated patients with respect to primary outcomes. The rate of preterm birth was 5.5% in the vaccinated group compared to 6.2% in the unvaccinated group (p = 0.31). Likewise, the rates of small for gestational age were comparable between the two groups (6.2% vs. 7.0% respectively, p = 0.2). In a secondary analysis focusing on time of vaccination and its relationship with outcomes, patients vaccinated in the second trimester (n = 964) and in the third trimester (n = 1329) were independently compared to their unvaccinated counterparts. Women who were vaccinated in the second trimester were more likely to have a preterm birth (8.1% vs. 6.2%, p < 0.001). This association persisted after adjusting for potential confounders (adjusted odds ratio 1.49, 95%CI 1.11, 2.01). Conclusions: SARS-CoV-2 vaccine appears to be safe during pregnancy with no increase in incidence of preterm labor and small for gestational age compared to unvaccinated women. However, in women vaccinated during the second trimester there may be an increase in the rate of preterm birth.

1 January 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
RHRani Haj-Yahya
Rani Haj-Yahya
HCHenry H. Chill
Henry H. Chill
Gabriel LevinGabriel Levin
Gabriel Levin
ARAdi Reuveni-Salzman
Adi Reuveni-Salzman
DSDavid Shveiky
David Shveiky

2 January 2021 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
HCHenry H. Chill
Henry H. Chill
GKGilad Karavani
Gilad Karavani
ARAdi Reuveni-Salzman
Adi Reuveni-Salzman
MLMichal Lipschuetz
Michal Lipschuetz
TSTzvika Shimonovitz
Tzvika Shimonovitz
DSDavid Shveiky
David Shveiky

6 February 2023 in Neurourology and Urodynamics
Verified
Journal Article
Open access
NMNani P. Moss
Nani P. Moss
HCHenry H. Chill
Henry H. Chill
PSPeter K. Sand
Peter K. Sand
CCCecilia Chang
Cecilia Chang
RGRoger P. Goldberg
Roger P. Goldberg
AGAdam Gafni‐Kane
Adam Gafni‐Kane
Introduction and Hypothesis: The primary aim of this study was to compare the effect of bladder instillations using dimethyl sulfoxide (DMSO) with triamcinolone versus bupivacaine, triamcinolone, and heparin (BTH) in women with newly diagnosed interstitial cystitis/painful bladder syndrome. The primary outcome was improvement in symptoms measured using the O'Leary‐Sant Interstitial Cystitis Symptoms Index (ICSI) score. Secondary comparisons included changes in urinary frequency, nocturia, and bladder capacity.Materials and Methods: This was a prospective, randomized study. Patients with a recent diagnosis of interstitial cystitis/painful bladder syndrome (IC/PBS) were randomized 1:1 to treatment with either 6 weekly bladder instillations of DMSO with triamcinolone or BTH. During follow‐up visits, patients completed the ICSI questionnaire, and bladder capacity was determined through the retrograde filling of the bladder. The χ2 test or Student's t test were used for data analysis.Results: A total of 83 patients were randomized, and final analysis included 70 participants who completed the 6 weekly instillations (42 DMSO, 28 BTH). The groups were similar in baseline demographics and clinical characteristics, except for cystometric maximum capacity (DMSO 338.62± 139.44 mL, BTH 447.43 ± 180.38 mL, p = 0.01). In the DMSO group, 63% of patients had a greater than 29.5% reduction in total ICSI score versus 43% in the BTH group (p = 0.15). Nocturia and pain were significantly reduced in the DMSO group. There was a significant increase from baseline in bladder capacity for both groups.Conclusion: In women with newly diagnosed IC/PBS, bladder instillations with DMSO and triamcinolone provide greater improvement in pain and nocturia compared to BTH.

12 March 2021 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
HCHenry H. Chill
Henry H. Chill
JGJoshua Guedalia
Joshua Guedalia
MLMichal Lipschuetz
Michal Lipschuetz
TSTzvika Shimonovitz
Tzvika Shimonovitz
RURon Unger
Ron Unger
GKGilad Karavani
Gilad Karavani